発表論文一覧

試験No 投稿誌 リファレンス 論文名 執筆者
2017年度(2017/4~2018/3)
1401 J Thorac Oncol 2017 12(7):1161-1166 Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401) 九州大学
岩間 映二
2018年度(2018/4~2019/3)
1201 Lung Cancer 132(2019)1-8 Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lu ng cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201) 長崎大学
福田 実
2019年度(2019/4~2020/3)
0403 The Oncologist doi 10,1634/
2019-0513t
Randomized, phase II study of weekly paclitaxel plus carboplatin versus biweekly paclitaxel plus carboplatin for patients with previously untreated advanced non-small cell lung cancer 京都府立医科大学病院
高山 浩一
0406 The Oncologist doi 10,1634/
2019-0717
Phase II study on biweekly combination therapy of gemcitabine plus carboplatin for the treatment of elderly patients with advanced non-small cell lung cancer 京都府立医科大学病院
高山 浩一
0408 Journal of
Clinical Medicin
2019,8,2196;
doi:10.3390/
jcm8122196.
Phase Ⅰ/II study of docetaxel and S-1 in previously-treated patients with advanced non-small cell lung cancer:LOGIK0408 京都府立医科大学病院
高山 浩一
1401-B The Oncologist 2019;24:1-9 Survival analysis for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance ststus treated with alectinib:Updated results of Lung Oncology Group in Kyushu1401 九州大学
岩間 映二
1605 Thoracic Cancer
(プロトコール論文)
11-2019-
3421.R1
S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma:study protocol of LOGIK1605/Tart-1501 長崎大学
福田 実
2020年度(2020/4~2021/3)
1101 The Oncologist 2020;25:1-10 Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101) 九州がんセンター
野崎 要
0602 BMC Cancer 20:1192
4-12-2020
A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study 長崎大学
土屋 智史
1603 BMC Cancer
(プロトコール論文)
(2020)20:370 A Phase II Study of Osimertinib for Patients with Radiotherapy-naive CNS Metastasis of Non-Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the OCEAN Study (LOGIK 1603/WJOG 9116L) 長崎大学
福田 実
1604 EJC Osimertinib Versus Osimertinib Plus Chemotherapy for Non-Small Cell Lung Cancer with EGFR (T790M)-Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-Label, Randomized Phase 2 Clinical Trial European Journal of Cancer 九州大学
田中 謙太郎